miR-423-3p inhibits CTNNBIP1/WNT preventing hyperandrogenic polycystic ovary syndrome
Oxford University Press (OUP)
Tässä tietueessa ei ole tiedostoja, ainoastaan metadata.
Pysyvä osoite
Verkkojulkaisu
Tiivistelmä
Polycystic ovary syndrome (PCOS) lacks the generally accepted diagnostic biomarkers and targeted therapy. Increasing evidence indicates that microRNAs play a crucial role in PCOS. Hereby, we tested the functional implications of a novel MicroRNA (miR-423-3p) as a mediator in the progress of hyperandrogenic PCOS, as well as its potential as a new serum biomarker and therapeutic target for the PCOS. We found significantly decreased miR-423-3p levels in serum, human granulosa cells (hGCs), and follicular fluid of PCOS patients (n = 40) compared to healthy controls (n = 30), and this decrease corroborated in PCOS-like mouse models. The receiver operating characteristic curve analysis for circulating miR-423-3p indicated high diagnostic potential as a biomarker, with an area under the curve of 82%. miR-423-3p influenced hGC (Human ovarian granulosa cell line KGN) proliferation by directly targeting CTNNBIP1-modulated Wingless-type (WNT) signaling pathway. We further proved as mechanistic role that the elevated dihydrotestosterone inhibited the expression of miR-423-3p via the activation of the androgen receptor, and the overexpression of miR-423-3p normalized the function of androgen-induced GCs. While we overexpressed miR-423-3p, it counteracted androgen-induced dysfunction in GCs. Antiandrogen treatment restored the reproductive phenotypes in letrozole-induced PCOS-like mice and regulated miR-423-3p expression and its downstream effects. Ovarian intrabursal injection of miR-423-3p antagomir in wild-type mice induced PCOS-like phenotypes, further underscoring its functional role. Our results demonstrated that miR-423-3p emerged as a novel mediator in hyperandrogenic PCOS progression, and it holds promise as both a diagnostic biomarker and a therapeutic target.Sentence miR-423-3p may play a novel role in hyperandrogen polycystic ovary syndrome (PCOS) progression, serving as a potential serum biomarker and therapeutic target. It helps prevent hyperandrogenic PCOS by inhibiting the CTNNBIP1/WNT signaling pathway.